Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Accenture
Fish and Richardson
Cantor Fitzgerald
Queensland Health
Harvard Business School
Healthtrust
McKinsey

Generated: May 24, 2018

DrugPatentWatch Database Preview

BETOPTIC S Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Betoptic S patents expire, and what generic alternatives are available?

Betoptic S is a drug marketed by Novartis Pharms Corp and is included in one NDA.

The generic ingredient in BETOPTIC S is betaxolol hydrochloride. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the betaxolol hydrochloride profile page.
Drug patent expirations by year for BETOPTIC S
Pharmacology for BETOPTIC S
Medical Subject Heading (MeSH) Categories for BETOPTIC S
Synonyms for BETOPTIC S
(.+/-.)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol
(+-)-1-(p-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)-2-propanol hydrochloride
(+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol
(+/-)-Betaxolol
(3-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-2-hydroxypropyl)(propan-2-yl)amine
1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol
1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)propan-2-ol
1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-isopropylaminopropan-2-ol hydrochloride
1-(4-[2-(Cyclopropylmethoxy)ethyl]phenoxy)-3-(isopropylamino)-2-propanol #
1-(Isopropylamino)-3-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)propan-2-ol hydrochloride
1-(isopropylamino)-3-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]propan-2-ol hydrochloride
1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)propan-2-ol
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)propan-2-ol hydrochloride
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)-2-propanol
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)-2-propanol hydrochloride
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol hydrochloride
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride
1-[4-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanol hydrochloride
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanolhydrochloride
1-{4-[2-(CYCLOPROPYLMETHOXY)ETHYL]PHENOXY}-3-(ISOPROPYLAMINO)PROPAN-2-OL
1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol
2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-
2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (+-)-
2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-,hydrochloride
2-Propanol,1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-
63659-18-7
63659-18-7 (Parent)
63659-19-8
63659-19-8 (hydrochloride)
659X187
659X198
72424-72-7
A803574
A834454
AB2000314
AB2000495
AC-1115
AC-1412
AC1L1DIZ
AC1L331T
AC1Q3DQ4
AKOS015841671
AKOS015843993
alo 1401-02
ALO-1401-02
AN-1136
AN-14973
API0001701
API0024704
AS-14125
AS-18082
B 5683
B4474
BC227944
BC227945
BCP0726000249
BCP9000394
BDBM50405521
beta-Xolol
Betaxolo Hydrochloride
betaxolol
Betaxolol (Betoptic)
Betaxolol (hydrochloride)
Betaxolol (INN)
Betaxolol (TN)
Betaxolol [INN:BAN]
Betaxolol for peak identification, European Pharmacopoeia (EP) Reference Standard
Betaxolol HCL
Betaxolol hydrochloride
Betaxolol hydrochloride (Betoptic)
Betaxolol hydrochloride (JP17/USP)
Betaxolol hydrochloride [USAN:USP:JAN]
Betaxolol hydrochloride [USAN]
Betaxolol hydrochloride, >98% (HPLC)
Betaxolol hydrochloride, European Pharmacopoeia (EP) Reference Standard
Betaxolol hydrochloride, United States Pharmacopeia (USP) Reference Standard
Betaxolol S
Betaxolol(hydrochloride)
Betaxololhydrochloride
Betaxololum
Betaxololum [INN-Latin]
Betazolol
Betoptic
Betoptic (TN)
Betoptic S (TN)
Betoptima
BG0105
BPBio1_000621
BRD-A02759312-003-03-9
BSPBio_000563
C-19113
C06849
C18H29NO3
CAS-63659-18-7
CC-24642
CCG-101057
CCG-204288
CCG-213473
CHDPSNLJFOQTRK-UHFFFAOYSA-N
CHEBI:3082
CHEBI:643228
CHEMBL1691
CHEMBL423
CPD000058420
CS-2452
CS-2453
CTK8F0838
CTK8F0839
D00598
D03ROX
D07526
DB00195
DR001279
DSSTox_CID_2674
DSSTox_GSID_22674
DSSTox_RID_76685
DTXSID2022674
EINECS 264-384-3
EU-0100193
FT-0601531
FT-0645228
GTPL549
HMS1569M05
HMS2089I07
HMS3655P17
HY-B0381
HY-B0381A
I06-1154
I14-16995
K005
KERLEDEX
Kerlon
Kerlone
Kerlone (TN)
Kerlong
KM0772
KS-00001F72
KS-00001F73
L000125
Lokren
Lokren ,Kerlone ;Betoptic
Lokren (TN)
Lopac0_000193
LP00193
LS-122005
LS-122006
MCI-144
MFCD00242959
MLS000028464
MLS000758269
MLS000863279
MLS001148209
MLS001424199
MLS002222261
MolPort-003-666-823
MolPort-003-845-027
MRF-0000336
NC00307
NCGC00015159-04
NCGC00015159-05
NCGC00015159-06
NCGC00015159-08
NCGC00015159-09
NCGC00015159-11
NCGC00024863-03
NCGC00024863-04
NCGC00093669-01
NCGC00093669-02
NCGC00260878-01
NSC-760048
NSC760048
NWIUTZDMDHAVTP-UHFFFAOYSA-N
Opera_ID_878
Pharmakon1600-01505512
Prestwick_779
Prestwick0_000382
Prestwick1_000382
Prestwick2_000382
Prestwick3_000382
Q-200713
Q-200714
S1827
s2091
SAM001247084
SC-23071
SCHEMBL23530
SCHEMBL42794
SL 75 212-10
SL 75.212-10
SL 75212
SL-75212
SL-75212-10
SMR000058420
SPBio_002484
SR-01000000108
SR-01000000108-4
ST51051256
TC-030604
TC-071428
Tox21_110091
Tox21_110091_1
Tox21_500193
W0012

US Patents and Regulatory Information for BETOPTIC S

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp BETOPTIC S betaxolol hydrochloride SUSPENSION/DROPS;OPHTHALMIC 019845-001 Dec 29, 1989 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for BETOPTIC S

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp BETOPTIC S betaxolol hydrochloride SUSPENSION/DROPS;OPHTHALMIC 019845-001 Dec 29, 1989 ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp BETOPTIC S betaxolol hydrochloride SUSPENSION/DROPS;OPHTHALMIC 019845-001 Dec 29, 1989 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
AstraZeneca
Federal Trade Commission
US Department of Justice
Colorcon
McKesson
Farmers Insurance
QuintilesIMS
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.